Incyte Corporation (INCY)

NASDAQ
Currency in USD
74.13
-0.82(-1.09%)
Closed
Pre Market
75.57+1.44(+1.94%)
INCY Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected today
Fair Value
Day's Range
73.7976.96
52 wk Range
50.3583.95
Key Statistics
Edit
Prev. Close
74.13
Open
75.37
Day's Range
73.79-76.96
52 wk Range
50.35-83.95
Volume
2.48M
Average Volume (3m)
1.87M
1-Year Change
28.56%
Book Value / Share
16.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INCY Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
79.92
Upside
+7.81%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

Incyte Corporation Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Employees
2524

Incyte Corporation SWOT Analysis


Pipeline Potential
Explore Incyte's diverse drug portfolio spanning hematology, oncology, and immunology, poised to drive future growth despite patent cliff challenges
Financial Resilience
Incyte's strong Q3 2024 results and $1.77B cash position underscore its financial health, with analysts noting the stock trades below fair value
Market Expansion
Delve into Incyte's strategic push into inflammation and immunology, targeting conditions like hidradenitis suppurativa with promising treatments
Analyst Outlook
Price targets range from $66 to $84, reflecting varied views on Incyte's ability to offset Jakafi revenue loss and capitalize on pipeline opportunities
Read full SWOT analysis

Incyte Corporation Earnings Call Summary for Q3/2024

  • Q3 2024 revenues up 24% YoY to $1.14B; net product revenues at $963M, driven by Jakafi and Opzelura growth
  • 2024 revenue guidance raised to $2.74B-$2.77B; R&D expenses at $573M including $100M milestone payment
  • Preparing for Niktimvo US launch in Q1 2025; aiming for ruxolitinib cream approval in pediatric atopic dermatitis H2 2025
  • Positive Phase 3 results for tafasitamab in follicular lymphoma; retifanlimab showed 37% risk reduction in SCAC
  • Multiple pivotal studies reporting in early 2025; expects significant revenue from diverse pipeline by 2029
Last Updated: 10/31/2024, 06:48 AM
Read Full Transcript

Compare INCY to Peers and Sector

Metrics to compare
INCY
Peers
Sector
Relationship
P/E Ratio
439.7x−2.5x−0.6x
PEG Ratio
−4.77−0.030.00
Price/Book
4.5x0.8x2.6x
Price / LTM Sales
3.5x12.6x3.1x
Upside (Analyst Target)
7.2%69.0%48.2%
Fair Value Upside
Unlock24.2%8.0%Unlock

Analyst Ratings

12 Buy
14 Hold
1 Sell
Ratings:
27 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 79.92
(+7.81% Upside)

Earnings

Latest Release
Oct 29, 2024
EPS / Forecast
1.07 / 1.03
Revenue / Forecast
1.14B / 1.08B
EPS Revisions
Last 90 days

People Also Watch

309.79
CEG
-0.64%
391.42
ELV
+0.24%
127.37
CAH
+0.25%
747.70
KLAC
-1.85%
107.66
FTNT
+2.81%

FAQ

What Is the Incyte (INCY) Stock Price Today?

The Incyte stock price today is 74.13

What Stock Exchange Does Incyte Trade On?

Incyte is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Incyte?

The stock symbol for Incyte is "INCY."

What Is the Incyte Market Cap?

As of today, Incyte market cap is 14.28B.

What is Incyte Earnings Per Share?

The Incyte EPS is 0.151.

What Is the Next Incyte Earnings Date?

Incyte will release its next earnings report on Feb 09, 2025.

From a Technical Analysis Perspective, Is INCY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.